Emicizumab — Discount Pricing

Other medications in Blood Disorders

• Epoetin Alfa
• Factor IX
• Factor VIII
• Filgrastim
• Hydroxyurea
• L-Glutamine
• Luspatercept
• Pegfilgrastim

About Emicizumab

Emicizumab is a prescription medication primarily used to prevent bleeding episodes in individuals with Hemophilia A. Hemophilia A is a rare, inherited bleeding disorder where the body doesn't produce enough clotting factor VIII, a protein essential for blood clot formation. This deficiency leads to prolonged bleeding after injuries, surgery, or even spontaneous bleeds, particularly into joints and muscles. Emicizumab is approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in both adults and children with Hemophilia A, regardless of whether they have developed factor VIII inhibitors (antibodies that neutralize replacement factor VIII). This broad applicability makes it a significant advancement for many patients who previously had limited effective treatment options, especially those with inhibitors.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Emicizumab is approved for (FDA label)

HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. HEMLIBRA is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: July 11, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Emicizumab (FDA label)

WARNING: THROMBOTIC MICROANGIOPATHY AND THROMBOEMBOLISM Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur. WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM See full prescribing information for complete boxed warning. Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.

Source: FDA prescribing information (DailyMed). Set ID: 2483adba-fab6-4d1b-96c5-c195577ed071. SPL document ID: 8f25ff10-e9d1-46a1-9889-e2c3f6e0d432. Label effective date: July 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Emicizumab (FDA label)

HEMLIBRA is available as a colorless to slightly yellow solution in single-dose vials. Injection: 12 mg/0.4 mL 30 mg/mL 60 mg/0.4 mL 105 mg/0.7 mL 150 mg/mL 300 mg/2 mL (150 mg/mL) Injection: 12 mg/0.4 mL in a single-dose vial ( 3 ) 30 mg/mL in a single-dose vial ( 3 ) 60 mg/0.4 mL in a single-dose vial ( 3 ) 105 mg/0.7 mL in a single-dose vial ( 3 ) 150 mg/mL in a single-dose vial ( 3 ) 300 mg/2 mL (150 mg/mL) in a single-dose vial ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 2483adba-fab6-4d1b-96c5-c195577ed071. SPL document ID: 8f25ff10-e9d1-46a1-9889-e2c3f6e0d432. Label effective date: July 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Emicizumab (FDA label)

The following serious adverse reactions are described elsewhere in the labeling: Thrombotic Microangiopathy Associated with HEMLIBRA and aPCC [see Warnings and Precautions (5.1) ] Thromboembolism Associated with HEMLIBRA and aPCC [see Warnings and Precautions (5.2) ] Most common adverse reactions (incidence ≥ 10%) are injection site reactions, headache, and arthralgia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 2483adba-fab6-4d1b-96c5-c195577ed071. SPL document ID: 8f25ff10-e9d1-46a1-9889-e2c3f6e0d432. Label effective date: July 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Emicizumab (FDA label)

None. None ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 2483adba-fab6-4d1b-96c5-c195577ed071. SPL document ID: 8f25ff10-e9d1-46a1-9889-e2c3f6e0d432. Label effective date: July 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Emicizumab (FDA label)

Immunogenicity: Anti-emicizumab antibodies (including neutralizing antibodies) have developed in HEMLIBRA-treated patients. In case of clinical signs of loss of efficacy, promptly assess the etiology and consider a change in treatment if neutralizing antibodies are suspected. ( 5.3 , 12.6 , 14.3 ) Laboratory Coagulation Test Interference: HEMLIBRA interferes with activated clotting time (ACT), activated partial thromboplastin time (aPTT), and coagulation laboratory tests based on aPTT, including one-stage aPTT-based single-factor assays, aPTT-based Activated Protein C Resistance (APC-R), and Bethesda assays (clotting-based) for factor VIII (FVIII) inhibitor titers. Intrinsic pathway clotting-based laboratory tests should not be used. ( 5.4 , 7.2 ) 5.1 Thrombotic Microangiopathy Associated with HEMLIBRA and aPCC Cases of thrombotic microangiopathy (TMA) were reported from clinical trials when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis.

Source: FDA prescribing information (DailyMed). Set ID: 2483adba-fab6-4d1b-96c5-c195577ed071. SPL document ID: 8f25ff10-e9d1-46a1-9889-e2c3f6e0d432. Label effective date: July 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Emicizumab (FDA label)

7.1 Hypercoagulability with Concomitant Use of aPCC Clinical experience suggests that a drug interaction exists with HEMLIBRA and aPCC [see Warnings and Precautions (5.1 , 5.2) ] . 7.2 Drug-Laboratory Test Interactions HEMLIBRA restores the tenase cofactor activity of missing activated factor VIII (FVIIIa). Coagulation laboratory tests based on intrinsic clotting (i.e., aPTT) measure the total clotting time including time needed for activation of FVIII to FVIIIa by thrombin. Such intrinsic pathway-based tests will yield overly shortened clotting times with HEMLIBRA, which does not require activation by thrombin. The overly shortened intrinsic clotting time will then disturb all single-factor assays based on aPTT, such as the one-stage FVIII activity assay; however, single-factor assays utilizing chromogenic or immuno-based methods are unaffected by HEMLIBRA and may be used to monitor coagulation parameters during treatment, with specific considerations for FVIII chromogenic activity assays as described below.

Source: FDA prescribing information (DailyMed). Set ID: 2483adba-fab6-4d1b-96c5-c195577ed071. SPL document ID: 8f25ff10-e9d1-46a1-9889-e2c3f6e0d432. Label effective date: July 11, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.